Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The heavy selling pressure might have exhausted for Revance Therapeutics (RVNC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround

The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%

MILWAUKEE , Aug. 15, 2024 /PRNewswire/ -- Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation https://www.ademilaw.com/case/revance-therapeutics-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Revance Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Revance Therapeutics , Inc. ( Nasdaq : RVNC ) , relating to its proposed merger with Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 in cash per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Revance Therapeutics, Inc. – RVNC

The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?

NEW YORK , Aug. 12, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Revance Therapeutics, Inc. (NASDAQ: RVNC) and its board of directors concerning the proposed acquisition of the company by Crown Laboratories, Inc. Stockholders will receive $6.66 for each share of Revance Therapeutics stock that they hold. The transaction is valued at approximately $924 million and is expected to close by the end of 2024.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.

Revance Therapeutics (NASDAQ: RVNC ) stock is on the rise Monday after the biotechnology company announced a merger agreement with private skincare company Crown Laboratories. This agreement has Crown Laboratories agreeing to acquire Revance Therapeutics for $924 million.

Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?

Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. RVNC.

Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Revance Therapeutics, Inc. (NASDAQ: RVNC) to Crown Laboratories, Inc. for $6.66 per share in cash is fair to Revance shareholders. Halper Sadeh encourages Revance shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether.

RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders

MONSEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance”) to Crown Laboratories, Inc. (“Crown”) for $6.66 per share in cash in a tender offer.

RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown Laboratories

Anti-wrinkle injection maker Revance Therapeutics will be acquired by private skincare company Crown Laboratories in a take-private deal worth $924 million, including debt, the two companies said on Monday.

Anti-wrinkle injection maker Revance to go private in $924 million deal

Combination provides opportunity to create a leading, innovative, high-growth  aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel New product flow potential through internal product development and an integrated manufacturing operation Experienced leadership team that leverages the strength of both organizations JOHNSON CITY, Tenn. and NASHVILLE, Tenn.

Crown Laboratories and Revance Announce Entry Into Merger Agreement

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laurence Watts - Investor Relations Mark Foley - Chief Executive Officer & President Tobin Schilke - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Chris Shibutani - Goldman Sachs Stacy Ku - TD Cowen David Amsellem - Piper Sandler Annabel Samimy - Stifel Lachlan Hanbury - William Blair Uy Ear - Mizuho Serge Belanger - Needham & Company Navann Ty - BNP Paribas Operator Welcome to the Revance Therapeutics Second Quarter 2024 Financial Results And Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Revance Therapeutics, Inc. (RVNC) Q2 2024 Earnings Call Transcript

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.80 per share a year ago.

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update.

Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024.

Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Beam Global

Backblaze

Just like in the sport of baseball, it's generally better to put one foot in front of the other: get on base and move the guy on first to second and so on until you score a run. However, if you're the San Diego Padres and you find yourself behind by 10 runs (usually to a terrible team), it's time to swing for the fences.

Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Investor Conferences.

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Context Therapeutics LLC

Design Therapeutics

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Caribou Biosciences

Verve Therapeutics

Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially.

3 Underappreciated Stocks That Could 10x in 10 Years

Revance Therapeutics Inc. (NASDAQ:RVNC ) Q1 2024 Results Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Laurence Watts - Investor Relations, New Street IR Mark Foley - Chief Executive Officer Tobin Schilke - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Partners Stacy Ku - TD Cowen Annabel Samimy - Stifel Financial Chris Shibutani - Goldman Sachs David Amsellem - Piper Sandler Daniel Ziment - Morgan Stanley Serge Belanger - Needham & Co. Lachlan Hanbury-Brown - William Blair Navann Ty - Exane BNP Paribas Operator Welcome to the Revance Therapeutics First Quarter2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.74 per share a year ago.

Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update.

News for Revance Therapeutics Stock (RVNC)